Cargando…
Sarcopenia in chronic kidney disease: what have we learned so far?
The term sarcopenia was first introduced in 1988 by Irwin Rosenberg to define a condition of muscle loss that occurs in the elderly. Since then, a broader definition comprising not only loss of muscle mass, but also loss of muscle strength and low physical performance due to ageing or other conditio...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357704/ https://www.ncbi.nlm.nih.gov/pubmed/32876940 http://dx.doi.org/10.1007/s40620-020-00840-y |
_version_ | 1783737186482388992 |
---|---|
author | Sabatino, Alice Cuppari, Lilian Stenvinkel, Peter Lindholm, Bengt Avesani, Carla Maria |
author_facet | Sabatino, Alice Cuppari, Lilian Stenvinkel, Peter Lindholm, Bengt Avesani, Carla Maria |
author_sort | Sabatino, Alice |
collection | PubMed |
description | The term sarcopenia was first introduced in 1988 by Irwin Rosenberg to define a condition of muscle loss that occurs in the elderly. Since then, a broader definition comprising not only loss of muscle mass, but also loss of muscle strength and low physical performance due to ageing or other conditions, was developed and published in consensus papers from geriatric societies. Sarcopenia was proposed to be diagnosed based on operational criteria using two components of muscle abnormalities, low muscle mass and low muscle function. This brought awareness of an important nutritional derangement with adverse outcomes for the overall health. In parallel, many studies in patients with chronic kidney disease (CKD) have shown that sarcopenia is a prevalent condition, mainly among patients with end stage kidney disease (ESKD) on hemodialysis (HD). In CKD, sarcopenia is not necessarily age-related as it occurs as a result of the accelerated protein catabolism from the disease and from the dialysis procedure per se combined with low energy and protein intakes. Observational studies showed that sarcopenia and especially low muscle strength is associated with worse clinical outcomes, including worse quality of life (QoL) and higher hospitalization and mortality rates. This review aims to discuss the differences in conceptual definition of sarcopenia in the elderly and in CKD, as well as to describe etiology of sarcopenia, prevalence, outcome, and interventions that attempted to reverse the loss of muscle mass, strength and mobility in CKD and ESKD patients. |
format | Online Article Text |
id | pubmed-8357704 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-83577042021-08-30 Sarcopenia in chronic kidney disease: what have we learned so far? Sabatino, Alice Cuppari, Lilian Stenvinkel, Peter Lindholm, Bengt Avesani, Carla Maria J Nephrol Review The term sarcopenia was first introduced in 1988 by Irwin Rosenberg to define a condition of muscle loss that occurs in the elderly. Since then, a broader definition comprising not only loss of muscle mass, but also loss of muscle strength and low physical performance due to ageing or other conditions, was developed and published in consensus papers from geriatric societies. Sarcopenia was proposed to be diagnosed based on operational criteria using two components of muscle abnormalities, low muscle mass and low muscle function. This brought awareness of an important nutritional derangement with adverse outcomes for the overall health. In parallel, many studies in patients with chronic kidney disease (CKD) have shown that sarcopenia is a prevalent condition, mainly among patients with end stage kidney disease (ESKD) on hemodialysis (HD). In CKD, sarcopenia is not necessarily age-related as it occurs as a result of the accelerated protein catabolism from the disease and from the dialysis procedure per se combined with low energy and protein intakes. Observational studies showed that sarcopenia and especially low muscle strength is associated with worse clinical outcomes, including worse quality of life (QoL) and higher hospitalization and mortality rates. This review aims to discuss the differences in conceptual definition of sarcopenia in the elderly and in CKD, as well as to describe etiology of sarcopenia, prevalence, outcome, and interventions that attempted to reverse the loss of muscle mass, strength and mobility in CKD and ESKD patients. Springer International Publishing 2020-09-02 2021 /pmc/articles/PMC8357704/ /pubmed/32876940 http://dx.doi.org/10.1007/s40620-020-00840-y Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Sabatino, Alice Cuppari, Lilian Stenvinkel, Peter Lindholm, Bengt Avesani, Carla Maria Sarcopenia in chronic kidney disease: what have we learned so far? |
title | Sarcopenia in chronic kidney disease: what have we learned so far? |
title_full | Sarcopenia in chronic kidney disease: what have we learned so far? |
title_fullStr | Sarcopenia in chronic kidney disease: what have we learned so far? |
title_full_unstemmed | Sarcopenia in chronic kidney disease: what have we learned so far? |
title_short | Sarcopenia in chronic kidney disease: what have we learned so far? |
title_sort | sarcopenia in chronic kidney disease: what have we learned so far? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357704/ https://www.ncbi.nlm.nih.gov/pubmed/32876940 http://dx.doi.org/10.1007/s40620-020-00840-y |
work_keys_str_mv | AT sabatinoalice sarcopeniainchronickidneydiseasewhathavewelearnedsofar AT cupparililian sarcopeniainchronickidneydiseasewhathavewelearnedsofar AT stenvinkelpeter sarcopeniainchronickidneydiseasewhathavewelearnedsofar AT lindholmbengt sarcopeniainchronickidneydiseasewhathavewelearnedsofar AT avesanicarlamaria sarcopeniainchronickidneydiseasewhathavewelearnedsofar |